News

<p>Moderna's 177% pop on a Phase 3 cancer-vaccine win rippled far beyond one stock.</p>

Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index decreasing 0.9% a

Profit-taking followed a record-setting rally sparked by the first successful Phase 3 trial of an mRNA cancer treatment.

Moderna’s breakthrough highlights a broader transformation, as AI accelerates the clinical development of therapies at a pace that would have seemed unimaginable a few years ago.

The trial met both endpoints in the readout, removing the inconclusive outcome management itself had flagged, and short sellers in the stock took a record single-session loss.

(Updates with latest market prices and developments.) US benchmark equity indexes fell intraday a

The rally around MRNA names began on Wednesday after Merck and Moderna reported positive late-stage results for their personalized mRNA cancer vaccine combined with Keytruda in high-risk melanoma patients.

Healthcare stocks declined Thursday afternoon, with the NYSE Healthcare Index decreasing 0.7% and th

The products meant to offset the KEYTRUDA patent expiry were named, and two were already booking revenue, before the stock moved.

Moderna stock surged following positive cancer-vaccine data, burning short sellers and spilling over into the semi sector.

BTIG analyst Mark Massaro raised the firm’s price target on Tempus AI to $80 from $70 and kept a Buy rating.

A new mRNA cancer vaccine hit its goal in melanoma patients, giving a healthcare giant a fresh growth story.

The medicines Pfizer has launched and acquired are arriving at close to the scale of the revenue its expiring patents will take away.

Moderna Inc (NASDAQ:MRNA, XETRA:0QF)'s melanoma trial success is prompting Wall Street to assign new platform value to the company's oncology pipeline, Jefferies said, as investors look beyond its COVID-dependent revenue base. The Jefferies note said intismeran vipatamotide (mRNA-4157), an...

Moderna and Merck scored a big win for their cancer vaccine on Wednesday. But analysts say it's too early to call it a home run.

Moderna's mRNA cancer vaccine sent shares on one of biotech's wildest two-day rides in years, but the brutal Thursday reversal raises a question investors now have to answer: does the science justify what the market priced in?

RBC Capital Markets analyst Trung Huynh downgrades shares of the Keytruda maker following a nearly 13% rally.

Merck's (MRK) strong momentum continues, driven by better-than-expected cancer vaccine data, but val

A historic one-session rally in a cancer vaccine stock is already unwinding, and Wall Street analysts disagree sharply on whether the reversal reflects a trade gone cold or an opportunity that the market is mispricing.

Merck and Moderna's personalized melanoma therapy meet key goals in phase III study, improving recurrence-free and distant metastasis-free survival in high-risk patients.

Moderna (MRNA) and Merck (MRK) reported promising results in their melanoma vaccine trial, sending the stocks soaring. BD8 Capital Partners CEO and CIO Barbara Doran and Yahoo Finance Markets and Data Editor Jared Blikre chat with Yahoo Finance Executive Editor Brian Sozzi about what the breakthrough could mean for Pfizer (PFE) and the larger healthcare sector.

Precigen's Papzimeos drives rapid revenue growth, while market exclusivity, global expansion and its pipeline add long-term potential.

RBC Capital noted that while the cancer vaccine results exceeded expectations, the stock’s $150 valuation is ‘unprecedented’ for a company facing a major loss of exclusivity in two years.

A landmark trial success for Moderna and Merck's cancer vaccine has strengthened the case for Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP), the immuno-oncology company developing a rival melanoma treatment, according to one broker covering the sector's innovative small-caps. Merck and...

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.5% and the actively tr

MRNA's cancer therapy scores a first phase III win, fueling hopes its mRNA platform can drive growth beyond COVID-19 vaccines.

Many Fed officials favor raising rates to combat inflation, bond prices surge, Trump meets crypto execs, and more news to start your day.

Pre-Market Stock Futures: Futures are trading lower after a wild day on Wall Street, as stocks took off after Treasury Secretary Bessent announced the Treasury would double its current bond buyback, targeting 10- to 20-year and 20- to 30-year maturities. That sparked an initial big rally, which tapered by the close; still, all of the ... Here Are Thursday’s Top Wall Street Analyst Research Calls: Alphabet, Analog Devices, Crown Castle, ebay, EPR Properties, Etsy, Merck & Co., Shopify, TJX Compan

Moderna tumbles as investors take some profit following Wednesday’s surge, while crypto stocks rally.

In August 2026, Merck and Moderna reported that their Phase 3 INTerpath-001 trial showed that individualized mRNA therapy intismeran (V940/mRNA-4157) plus KEYTRUDA improved recurrence-free and distant metastasis-free survival in patients with completely resected stage IIB–IV melanoma versus KEYTRUDA alone. This marks the first successful Phase 3 result for both an individualized neoantigen mRNA cancer therapy and an mRNA treatment outperforming a standard-of-care immunotherapy in the...